Product Datasheet

Oditrasertib

Catalog No. **BP-00101** · CAS **2252271-93-3** · Form **free base** · Physical state **solid** · Color **white to off-white** · Version **1.0** · Revision **2026-09-10**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
RIP kinase	**Neurological Disease; Inflammation/Immunology**

Molecular formula	**$C_{14}H_{15}F_2N_3O_2$**
Molecular weight	**295.2846**

STRUCTURE



DESCRIPTION

Oditrasertib (SAR443820) is an orally active, BBB-penatrable and selective reversible inhibitor of RIPK1. Oditrasertib can be used in the research of chronic inflammatory central nervous system diseases, such as amyotrophic lateral sclerosis and multiple sclerosis.

BIOLOGICAL ACTIVITY

In Vitro

Oditrasertib has a 50% inhibitory concentration of 3.16 nM in human PBMCs and 1.6 nM in iPSC-derived microglia.

SOLUBILITY

Soluble in DMSO

REFERENCES

[1]. Fidalgo JDV, et al. Preparation of substituted oxazepines and related compounds as RIPK1 inhibitors and uses thereof. WO2018213632A1. 2018-11-22.

[2]. Hincelin-Mery A, et al. Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants. Clin Transl Sci. 2024 Jan;17(1):e13690.

[3]. Montalban X, et al. Effect of RIPK1 inhibitor, SAR443820, on serum neurofilament light levels in patients with multiple sclerosis: a phase 2 trial design (P6-3.011)[J]. Neurology, 2023, 100(17_supplement_2): 2178.